(Q40473651)

20 September 2017

Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. (English)

1 reference

20 September 2017

10

Paul Richardson

1 reference

20 September 2017

11

Kenneth C Anderson

1 reference

20 September 2017

7

Shaji Kumar

1 reference

20 September 2017

6

Noopur Raje

1 reference

20 September 2017

8

Dharminder Chauhan

1 reference

20 September 2017

2

Teru Hideshima

1 reference

20 September 2017

5

Hiroshi Yasui

1 reference

20 September 2017

4

Klaus Podar

1 reference

20 September 2017

9

Steven P Treon

1 reference

20 September 2017

3

Masaharu Akiyama

1 reference

20 September 2017

Toshiaki Hayashi

1

1 reference

PubMed ID

15638853

20 September 2017

language of work or name

English

0 references

publication date

1 January 2005

1 reference

British Journal of Haematology

20 September 2017

1 reference

20 September 2017

128

1 reference

20 September 2017

192-203

1 reference

20 September 2017

2

1 reference

Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha

20 September 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05286.X

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05286.X

Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05286.X

Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05286.X

Natural killer cells, viruses and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05286.X

Regulation of protein kinase C zeta by PI 3-kinase and PDK-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05286.X

Requirement for transcription factor NFAT in interleukin-2 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05286.X

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05286.X

Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05286.X

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05286.X

Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05286.X

Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05286.X

Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05286.X

Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05286.X

Ex vivo induction of multiple myeloma–specific cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05286.X

Molecular mechanisms of novel therapeutic approaches for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05286.X

NF-kappa B as a therapeutic target in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05286.X

Pivotal role of phosphoinositide-3 kinase in regulation of cytotoxicity in natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05286.X

Phosphatidylinositol 3-kinase p85 adaptor function in T-cells. Co-stimulation and regulation of cytokine transcription independent of associated p110.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05286.X

Immunomodulatory drug costimulates T cells via the B7-CD28 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05286.X

Partners in transcription: NFAT and AP-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05286.X

Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05286.X

CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05286.X

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05286.X

Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05286.X

Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05286.X

Allogeneic stem cell transplantation reduces disease progression compared to autologous transplantation in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05286.X

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05286.X

Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05286.X

Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05286.X

CD20-Directed Serotherapy in Patients With Multiple Myeloma: Biologic Considerations and Therapeutic Applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05286.X

Structure and function of phosphoinositide 3-kinases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05286.X

T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05286.X

10.1111/J.1365-2141.2004.05286.X

21 January 2018

Identifiers

DOI

1 reference

20 September 2017

1 reference

PubMed ID

15638853